Dopamine-dependent early synaptic and motor dysfunctions induced by α-synuclein in the nigrostriatal circuit
Open Access
- 23 July 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in Brain
- Vol. 144 (11), 3477-3491
- https://doi.org/10.1093/brain/awab242
Abstract
Misfolding and aggregation of α-synuclein are specific features of Parkinson’s disease and other neurodegenerative diseases defined as synucleinopathies. Parkinson’s disease progression has been correlated with the formation and the extracellular release of α-synuclein aggregates, as well as with their spreading from neuron to neuron. Therapeutic interventions in the initial stages of Parkinson’s disease require a clear understanding of the mechanisms by which α-synuclein disrupts the physiological synaptic and plastic activity of the basal ganglia. For this reason, here we have identified two early time points to clarify how the intrastriatal injection of α-synuclein preformed fibrils in rodents, via retrograde transmission, induces time-dependent electrophysiological and behavioral alterations. We found that intrastriatal α-synuclein preformed fibrils perturb the firing rate of dopaminergic neurons of the substantia nigra pars compacta while the discharge of putative GABAergic cells of the substantia nigra pars reticulata is unchanged. The α-synuclein-induced dysregulation of nigrostriatal function also impairs, in a time-dependent manner, the two main forms of striatal synaptic plasticity, long-term potentiation and long-term depression. We also observed an increased glutamatergic transmission measured as an augmented frequency of spontaneous excitatory synaptic currents. These changes in neuronal function in the substantia nigra pars compacta and striatum were observed before overt neuronal death occurred. In an additional set of experiments, we were able to rescue α-synuclein-induced alterations of motor function, striatal synaptic plasticity, and increased spontaneous excitatory synaptic currents by a sub-chronic treatment with L-Dopa, a precursor of dopamine widely used in the therapy of Parkinson’s disease, clearly demonstrating that a dysfunctional dopamine system plays a critical role in the early phases of the disease.Keywords
Funding Information
- Marlene and Paolo Fresco
- Ministero dell’Istruzione, dell’Università e della Ricerca (2017ENN4FY)
- Ministero della Salute
- NIH (NS045962)
- Fondazione Roma and Regione Umbria
This publication has 48 references indexed in Scilit:
- Deficits in dopaminergic transmission precede neuron loss and dysfunction in a new Parkinson modelProceedings of the National Academy of Sciences of the United States of America, 2013
- Pathological α-Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic MiceScience, 2012
- Direct Observation of the Interconversion of Normal and Toxic Forms of α-SynucleinCell, 2012
- Motor signs in the prodromal phase of Parkinson's diseaseMovement Disorders, 2012
- Exogenous α-synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cellsProceedings of the National Academy of Sciences of the United States of America, 2009
- Interplay between Cytosolic Dopamine, Calcium, and α-Synuclein Causes Selective Death of Substantia Nigra NeuronsNeuron, 2009
- Levodopa therapy for Parkinson's disease: Challenges and future prospectsMovement Disorders, 2008
- Dichotomous Dopaminergic Control of Striatal Synaptic PlasticityScience, 2008
- Dopamine-mediated regulation of corticostriatal synaptic plasticityTrends in Neurosciences, 2007
- Frequency-specific and D 2 receptor-mediated inhibition of glutamate release by retrograde endocannabinoid signalingProceedings of the National Academy of Sciences of the United States of America, 2006